Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

A Multi-Center, Double-Blind, Placebo-Controlled Safety and Preliminary Efficacy Study of IL-1 Trap (Rilonacept) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00609544

Enrollment

Registered

2008-02-07

Start date

Unknown

Completion date

Unknown

Last updated

2011-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia, Chronic Kidney Disease

Keywords

Non Dialysis-dependent chronic kidney disease and anemia

Brief summary

Anemia of inflammation is a common complication in patients with chronic kidney disease (CKD). Patients with CKD and anemia of inflammation also exhibit decreased response to erythropoietic agents, even in the presence of adequate iron stores. This decreased responsiveness is associated with increased levels of proinflammatory cytokines. Rilonacept is being developed for the treatment of inflammatory disorders. This is a clinical research study to determine the safety and effectiveness of rilonacept for the treatment of anemia in inflamed patients with CKD who are not yet on dialysis.

Interventions

DRUGRilonacept

Loading dose of 320 mg Rilonacept or placebo followed by 160 mg Rilonacept or placebo once a week for 11 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or female greater than 18 years of age * Chronic Kidney Disease (CKD) not yet requiring renal replacement therapy (pre-dialysis patients) * Not expected to require dialysis during duration of the study * Adequate laboratory values * If on rHuEPO therapy, the dose must be stable

Exclusion criteria

* Persistent chronic or active infections * Intravenous (IV) iron administration within 12 weeks prior to the Screening Visit * Known history of severe uncontrolled hyperparathyroidism * Prior recipient or scheduled to receive a kidney transplant during the study * Abnormal laboratory values * Unstable angina or myocardial infarction within the past 6 months prior to the Screening Visit * Uncontrolled hypertension * Coronary disease diagnosed in the 3 months prior to the Screening Visit * Severe Congestive Heart Failure * History of HIV * Hepatitis B and/or Hepatitis C * Abnormal chest radiograph * A positive intradermal skin tuberculin test * History or presence of cancer within 5 years of the Screening Visit * History of alcohol abuse or current intake of 21 or more alcohol-containing drinks per week * History of drug abuse within the 5 years prior to the Screening Visit * Lactating females or pregnant females

Design outcomes

Primary

Measure	Time frame
Change in blood hemoglobin concentration.	Baseline to Week 12

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026